Key result
In-stent CTO PCI linked to ~2.4-fold higher 36-month MACE rates versus de novo CTO.
Cohort (n=483)
Answers are grounded in this paper and cite their sources.
Demonstrates higher adverse cardiac event rates in patients with in-stent versus de novo chronic total occlusion, indicating poorer long-term anginal stability.
Limited data are available on long-term outcomes and health status in the treatment of in-stent coronary chronic total occlusion (IS-CTO) and de novo coronary chronic total occlusion (de novo CTO). This study compared the long-term clinical outcomes and health status of percutaneous coronary intervention (PCI) for patients with IS-CTO versus patients with de novo CTO in the drug-eluting stent era. We screened 483 consecutive patients with 1 CTO lesion, including 81 patients with IS-CTO and 402 patients with de novo CTO. Propensity score matching was used to balance baseline characteristics between the 2 groups. The clinical end point was major adverse cardiac events (MACE). The success rates of CTO lesion revascularization were similar in both groups. In the propensity score-matched patients, after a median follow-up of 36 months, MACE was observed in 32.8% of patients with IS-CTO versus 13.5% of the patients with de novo CTO ( P < .001), mainly driven by target-vessel revascularization (21.9% vs 6.7%; P < .01). Moreover, patients with IS-CTO had significantly worse Seattle Angina Questionnaire anginal stability scores than the patients with de novo CTO. In conclusion, patients with IS-CTO after PCI had a worse clinical outcome, mainly MACE, and a poorer anginal stability in the long term than patients with de novo CTO.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2021) conducted a cohort in Coronary chronic total occlusion (n=483). Percutaneous coronary intervention for in-stent chronic total occlusion (IS-CTO) vs. Percutaneous coronary intervention for de novo chronic total occlusion (de novo CTO) was evaluated on Major adverse cardiac events (MACE) (p=<0.001). Patients with in-stent CTO undergoing PCI had higher rates of major adverse cardiac events at 36 months compared to de novo CTO (32.8% vs 13.5%; P<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: